Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879316 | 0.83 | GAA (0.62) | MAPTTDP1GAAALDH1A1 | |
| SCHEMBL217079 | 0.83 | CYP3A4 (0.56) | CYP3A4TP53TSHRMAOBGAA | |
| SCHEMBL3312611 | 0.82 | MAPT (0.54) | MAPTTP53TDP1TSHRPSEN1 | |
| SCHEMBL8770574 | 0.81 | MAPT (0.67) | MAPTTP53TDP1TSHRPSEN1 | |
| SCHEMBL272026 | 0.80 | MAPT (0.81) | MAPTTSHRPSEN1PSEN2APH1B | |
| SCHEMBL655678 | 0.80 | TP53 (0.62) | MAPTCYP3A4TP53TSHRMAOB | |
| SCHEMBL29577774 | 0.80 | TP53 (0.62) | MAPTCYP3A4TP53TSHRMAOB | |
| SCHEMBL20685285 | 0.80 | MAPT (0.57) | MAPTTP53TDP1TSHRPSEN1 | |
| SCHEMBL1949826 | 0.79 | MAPT (0.54) | MAPTTP53TDP1PSEN1PSEN2 | |
| SCHEMBL10753958 | 0.79 | CYP3A4 (0.59) | CYP3A4TP53TSHRMAOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714238-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160340347-A9 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-9388153-B2 | Secondary amines as therapeutic agents | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388153-B2 | Secondary amines as therapeutic agents | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388153-B2 | Secondary amines as therapeutic agents | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| WO-2015094864-A1 | SECONDARY AMINES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094864-A1 | SECONDARY AMINES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175586-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175567-A1 | SECONDARY AMINES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175567-A1 | SECONDARY AMINES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175567-A1 | SECONDARY AMINES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-8633220-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633220-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012003145-A2 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175567-A1 | SECONDARY AMINES AS THERAPEUTIC AGENTS | PDE6G, PDE3A, TYR | MAPT 227/4885CYP3A4 1809/4885TP53 1636/4885 |
| US-20150175586-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | MAPT 3262/4885CYP3A4 3609/4885TP53 4243/4885 |
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | MAPT 3517/4885CYP3A4 44/4885TP53 882/4885 |
| US-20160340347-A9 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | MAPT 3262/4885CYP3A4 3609/4885TP53 4243/4885 |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | MAPT 3262/4885CYP3A4 3609/4885TP53 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.